Here again, we have partnered with SpectraCell Labs again to bring you the best and most complete testing available on the market.
Prediction of cardiovascular disease remains an elusive target for physicians and other advanced practitioners. One of the primary factors in all prediction models is cholesterol. However, any physician will tell you that prediction of cardiac risk is much more involved than simply determining a person’s LDL (bad) and HDL (good) numbers. In one of the earliest studies performed in 2001 by the National Institute of Health looking at the significance of cholesterol, they reported that almost 50% of participants in the study who had heart attacks had “normal” cholesterol levels at the time of their heart attack. This has led to further research and constantly changing guidelines for therapy on these topics.
Much more recently, the National Cholesterol Education Program (NCEP) has published recommendations and data supporting 4 primary targets to be added to standardized cholesterol screenings for better prediction of cardiovascular risk. These four particles are small, dense LDL, Lipoprotein A, Remnant Lipoprotein, and HDL2b. SpectraCell’s proprietary Lipoprotein Particle Profile (LPP) has been developed in response to this recommendation and tests all 4 of these cholesterol microparticles. This, in turn, can help guide you in your need for dietary and lifestyle changes to help prevent the long-term complications that come from developing atherosclerotic vascular disease in the heart and elsewhere.
Additionally, the complete cardiometabolic profile that we test includes vascular inflammatory markers ApoB-100, hsCRP, and homocysteine, as well as early markers for prediabetes that go above and beyond a simple A1c and blood glucose test. In testing these commonly overlooked items, you will be empowered to intervene and make life-style changes before you are affected by these terrible diseases.